New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2013
19:02 EDTHEK, DMND, EMAN, PWRD, PAY, YUM, IRBT, STEI, BIOS, LAKEOn The Fly: After Hours Movers
UP AFTER EARNINGS: Heckmann (HEK), up 10.2%... BioScrip (BIOS), up 8.2%... Stewart Enterprises (STEI), up 3.5%... ALSO HIGHER: iRobot (IRBT), up 9.1% after appointing a new CFO and raising its Q1 earnings per share outlook to 16c-20c from 0c-7c... Yum! Brands (YUM), up 6.7% after the company reported better-than-expected Q1 China same-store sales... Verifone (PAY), up 6.3% after announcing its CEO would step down and the company backed its Q2 and FY13 sales and earnings forecasts... DOWN AFTER EARNINGS: Perfect World (PWRD), down 10.3%... eMagin (EMAN), down 9.8%... Diamond Foods (DMND), down 5.1%... ALSO LOWER: Lakeland Industries (LAKE), down 23.1% after announcing an $11.5M goodwill impairment charge.
News For HEK;BIOS;STEI;IRBT;YUM;PAY;PWRD;EMAN;DMND;LAKE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 23, 2014
15:25 EDTLAKENew York confirms health care worker being tested for Ebola
Subscribe for More Information
14:58 EDTLAKENew York doctor rushed to hospital with Ebola-like symptoms, NY Post reports
Subscribe for More Information
08:01 EDTYUMMcDonald's pressured by rising competition in China, WSJ says
In addition to its food supplier issues, McDonald’s (MCD) has a bigger problem in China, namely rising competition from other foreign companies such as Yum! (YUM) and domestic chains that have gained prominence and scale, said The Wall Street Journal. Reference Link
06:22 EDTLAKEEU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
October 22, 2014
12:09 EDTIRBTOn The Fly: Midday Wrap
Subscribe for More Information
09:21 EDTIRBTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
06:54 EDTLAKEProtection equipment makers see sales rise amid Ebola situation, NY Times says
Subscribe for More Information
October 21, 2014
18:36 EDTIRBTOn The Fly: After Hours Movers
Subscribe for More Information
17:08 EDTIRBTiRobot trades higher after results, first look
Price is up in the extended session by 7.5% following results and guidance, last at $34.10. At that price next resistance is at $35.73. Support is at $33.28.
16:16 EDTIRBTiRobot trades higher after results, first look
Subscribe for More Information
16:12 EDTIRBTiRobot raises FY14 EPS view to $1.20-$1.25 from $1.10 - $1.20, consensus $1.14
Subscribe for More Information
16:10 EDTIRBTiRobot sees Q4 EPS 26c-31c, consensus 35c
Sees Q4 revenue $158M - $167M , consensus $167.84M
16:09 EDTIRBTiRobot reports Q3 EPS 48c, consensus 33c
Subscribe for More Information
07:21 EDTLAKEiBio valuation will be hard to maintain, TheStreet's Feuerstein says
iBio's current valuation will be hard to maintain "even under the best Ebola stockpiling scenario," TheStreet's Adam Feuerstein argues. He notes Ebola related stocks fell yesterday after the quarantines related to Thomas Duncan ended. Reference Link
October 20, 2014
14:29 EDTLAKELakeland Industries management to meet with Philadelphia Securities Association
Subscribe for More Information
12:28 EDTPAYNCR Corp. plummets after guidance lowered
Shares of payment solutions company NCR Corp. (NCR) are sinking after the firm’s third quarter forecasts missed analysts’ consensus estimates and it lowered its outlook for fiscal 2014. WHAT'S NEW: This morning, NCR Corp. forecast Q3 EPS of 67c and revenue of $1.647B, below analysts' consensus estimates of 71c and $1.66B, respectively. Q3 free cash flow is seen at $132M, which includes the previously announced recovery of $93M related to the Fox River environmental matter. The company cited a challenging retail market as well as difficult global macroeconomic conditions, including foreign currency headwinds, for the weak outlook. WHAT'S NOTABLE: NCR Corp. lowered its FY14 EPS view to $2.60-$2.70 from $3.00-$3.10, compared to consensus of $3.00. It also cut its FY14 revenue outlook to $6.575B- $6.625B from $6.75B-$6.85B, versus consensus of $6.74B. The company said, “While we are disappointed by these results, our Financial Services business remains a bright spot, Q3 free cash flow improvement was strong, and our previously announced restructuring program is on track to deliver annual run-rate savings of approximately $90M by 2016. While we continue to be faced with challenging and uncertain market dynamics, we remain confident in the actions we are taking to address these challenges, including strengthening our Retail Solutions team and talent, as well as utilizing our restructuring program to allocate more resources to our highest growth, highest margin opportunities to drive long-term profitable growth.” PRICE ACTION: In afternoon trading, NCR Corp. fell $6.43, or about 21.5%, to $23.45 on nearly five times its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week low of $23.32. Including today's pull back, the shares have lost approximately 41% over the past 12 months. OTHERS TO WATCH: Other companies in the payment solutions business include VeriFone Systems (PAY) and Diebold (DBD).
09:08 EDTIRBTiRobot awarded $7.6M order for upgrades and spares for 46 MTRS
Subscribe for More Information
October 17, 2014
11:25 EDTPAYVeriFone wins appeal of patent ruling in favor of CardSoft
Subscribe for More Information
09:46 EDTLAKESarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
08:00 EDTPAYVeriFone fundamentals unchanged despite sell-off, says Jefferies
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use